Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04570423 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
A Phase 2 study of Lymphoma and Solid Tumors, sponsored by Spectrum Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 5
- Study locations
NCT04570423 is a Phase 2 study of Lymphoma and Solid Tumors that is actively recruiting participants, run by Spectrum Pharmaceuticals. The registered enrollment target is 40 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT04570423, a Phase 2 study of Lymphoma and Solid Tumors, is actively recruiting participants, sponsored by Spectrum Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Conditions Studied
Interventions
- DRUG Chemotherapy
- DRUG Eflapegrastim
Study Locations (5)
North Carolina
- Carolinas Medical Center/ Levine Children's Hospital - Charlotte
- Levine Children's Health - Charlotte
New York
- New York Medical College - Valhalla
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-05-20 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04570423
The ClinicalTrials.gov registry entry for NCT04570423 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy is the first listed.
NCT04570423 reports 5 study locations spanning 4 distinct geographic areas - top geographies include North Carolina, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT04570423 about?
NCT04570423 is a clinical study titled "A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy". The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
What is the current status of trial NCT04570423?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-05-20. Estimated completion is 2027-10.
What conditions does trial NCT04570423 study?
This clinical trial studies the following conditions: Lymphoma, Solid Tumors.
What interventions are being tested in trial NCT04570423?
The interventions under investigation include: Chemotherapy (DRUG), Eflapegrastim (DRUG).
Who is sponsoring clinical trial NCT04570423?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04570423 being conducted?
This trial has 5 study locations across New York, North Carolina, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.